• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Rilutek (riluzole)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Rilutek (riluzole)

  • Profile

Profile

Contact Information

Contact: Covis Pharma
Website: https://covispharma.com/

Currently Enrolling Trials

    Show More

    General Information

    Rilutek (riluzole) is a member of the benzothiazole class.

    Rilutek is specifically indicated for the treatment of amyotrophic lateral sclerosis (ALS).

    Rilutek is supplied as tablets for oral administration. The recommended dosage is 50 mg twice daily, taken at least 1 hour before or 2 hours after a meal.

    Mechanism of Action

    Rilutek (riluzole) is a member of the benzothiazole class. The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown.

    Side Effects

    Adverse effects associated with the use of Rilutek may include, but are not limited to, the following:

    • asthenia
    • nausea
    • dizziness
    • decreased lung function
    • abdominal pain

    Clinical Trial Results

    The efficacy of Rilutek was demonstrated in two studies (Study 1 and 2) that evaluated Rilutek 50 mg twice daily in patients with amyotrophic lateral sclerosis (ALS). Both studies included patients with either familial or sporadic ALS, a disease duration of less than 5 years, and a baseline forced vital capacity greater than or equal to 60% of normal.

    Study 1 was a randomized, double-blind, placebo-controlled clinical study that enrolled 155 patients with ALS. Patients were randomized to receive Rilutek 50 mg twice daily (n=77) or placebo (n=78) and were followed for at least 13 months (up to a maximum duration of 18 months). The clinical outcome measure was time to tracheostomy or death.

    The time to tracheostomy or death was longer for patients receiving Rilutek compared to placebo. There was an early increase in survival in patients receiving Rilutek compared to placebo. Among the patients in whom the endpoint of tracheostomy or death was reached during the study, the difference in median survival between the Rilutek 50 mg twice daily and placebo groups was approximately 90 days.

    Study 2 was a randomized, double-blind, placebo-controlled clinical study that enrolled 959 patients with ALS. Patients were randomized to Rilutek 50 mg twice daily (n=236) or placebo (n=242) and were followed for at least 12 months (up to a maximum duration of 18 months). The clinical outcome measure was time to tracheostomy or death.

    The time to tracheostomy or death was longer for patients receiving Rilutek compared to placebo. Among the patients in whom the endpoint of tracheostomy or death was reached during the study, the difference in median survival between Rilutek and placebo was approximately 60 days.

    Although Rilutek improved survival in both studies, measures of muscle strength and neurological function did not show a benefit.

    Approval Date: 1995-12-01
    Company Name: Covis Pharma
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing